Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Japanese Journal of Clinical Oncology|March 13, 2013
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neckSusumu Okano, Takayuki Yoshino, Masato Fujii, et al.
Japanese Journal of Clinical Oncology|February 3, 2007
The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancerKentaro Yamazaki, Narikazu Boku, Kaoru Shibamoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 13, 2015
Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapyHiroyuki Tabuse, Hiroya Kashiwagi, Satoshi Hamauchi, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2016
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancerTakeshi Kawakami, Nozomu Machida, Hirofumi Yasui, et al.
Annals of Surgical Oncology|January 8, 2015
Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomySatoru Matsuda, Yasuhiro Tsubosa, Masahiro Niihara, et al.
International Journal of Clinical Oncology|March 11, 2010
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysisTakeshi Sakamoto, Hirofumi Yasui, Narikazu Boku, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 5, 2010
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatinRai Shimoyama, Hirofumi Yasui, Narikazu Boku, et al.
Investigational New Drugs|April 9, 2021
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancerHiroto Inoue, Akiko Todaka, Kentaro Yamazaki, et al.
The Oncologist|July 9, 2024
Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapySatoshi Suzuki, Tomoya Yokota, Akifumi Notsu, et al.
International Journal of Clinical Oncology|December 22, 2005
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxelMasaki Matsuoka, Narikazu Boku, Takayuki Yoshino, et al.
Pageof 11